Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C23H20N2O2
CAS Number:
Molecular Weight:
356.42
NACRES:
NA.21
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Application
DCZ0415 may be used to determine its effects on cell viability, cell cycle distribution, invasive capabilities, and migratory behavior of colorectal cancer (CRC) cells.
Biochem/physiol Actions
DCZ0415 also reduces cyclin D1, β-catenin, and T-cell factor 1 levels, resulting in the inactivation of the Wnt/β-catenin pathway.
DCZ0415 is a TRIP13 inhibitor that exhibits antimyeloma activity in cultures (IC50 in µM = 1.15/U266, 3.25/ARK, 4.13/OCI-MY5, 5.12/ARP-1, 7.4/RPMI-8226, H292/8.02) and in xenograft models in vivo (25 or 50 mg/kg via daily i.p. to mice with MOPC-315 or H929 tumors, respectively) by impairing nonhomologous end-joining (NHEJ) repair and NF-kB activity. Synergistic antimyeloma activity is observed when DCZ0415 is used in combination with the DNA-akylating agent melphalan or the HDAC inhibitor panobinostat.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yan Chen et al.
Cell death discovery, 8(1), 35-35 (2022-01-26)
Colorectal cancer (CRC) is one of the digestive tract malignancies whose early symptoms are not obvious. This study aimed to identify novel targets for CRC therapy, especially early-stage CRC, by reanalyzing the publicly available GEO and TCGA databases. Thyroid hormone
Yingcong Wang et al.
Cancer research, 80(3), 536-548 (2019-11-17)
The AAA-ATPase TRIP13 drives multiple myeloma progression. Here, we present the crystal structure of wild-type human TRIP13 at a resolution of 2.6 Å. A small-molecule inhibitor targeting TRIP13 was identified on the basis of the crystal structure. The inhibitor, designated
Sumit Agarwal et al.
Molecular oncology, 16(8), 1728-1745 (2022-02-24)
Thyroid receptor-interacting protein 13 (TRIP13), a protein of the AAA-ATPase family, is upregulated in various human cancers, including colorectal cancer (CRC). This study focused on the inhibition of TRIP13-induced CRC progression and signalling by DCZ0415, a small molecule targeting TRIP13.
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML4195-5MG | 04065272818360 |
| SML4195-25MG | 04065272818353 |